Solid Tumors

Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners

Lindsay Dougherty,(1) CRNP, DNP, Whitney E. Lewis,(2) PharmD, BCOP, Meghan O’Neill,(1) CRNP, MSN, Amitabha Bhaumik,(3) PhD, Denise D’Andrea,(3) MD, and Andy L. Johnson,(3) PhD

Many targeted therapies to treat genetic mutations in non–small cell lung cancer (NSCLC) have been developed. Amivantamab(Rybrevant), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial ...

Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma

Jillian Hunt, MSN, APRN, FNP-C, AOCNP®

Melanoma is the fifth most common cancer in the United States, with over 7,000 deaths annually. Although most patients diagnosed with early-stage (stage I or II) disease have an excellent prognosis, two out of three patients who die from...

Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer

Presented by Stephanie L. Graff,(1,2) MD, FACP, FASCO, Christine McGinn,(1) MSN, APRN, ACNP-BC, and Jeanine R. Showalter,(3) MSN, APRN, FNP-BC, AOCNP®

At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status,...

Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice

Presented by Mary B. Morgan,(1) MSN, ANP-BC, AOCN®, and Tammy Triglianos,(2) DNP, ANP-BC, AOCNP®

At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider...

Advancing Precision-Targeted Treatment for Patients With Metastatic Non–Small Cell Lung Cancer

Presented by Tajuana Bradley,(1) MSN, APRN-BC, and Beth Sandy,(2) MSN, CRNP, FAPO

At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecu...

Improving Prostate Cancer Patient Care in the Clinical Setting

Presented by Jessica Deinert, MSN, APRN, FNP-C, AOCNP®, and Leah K. Shaw, MSN, APRN, AGPCNP-BC

At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies ba...

Maintaining Survival While Improving Quality of Life: An Advanced Practitioner–Led Pilot Feasibility Study to Reduce Radiation Dose in Children With Brain Tumors

Jennifer L. Raybin,(1) PhD, RN, CPNP, Andrew Donson,(1) Nicholas K. Foreman,(1) MRCP, Rajeev Vibhakar,(1) MD, Michael H. Handler,(1) MD, and Arthur K. Liu,(2) MD, PhD

Purpose: Oncology advanced practitioners (APs) are on the front line in treating adverse effects. Among children with brain tumors, treatments such as craniospinal irradiation (CSI) cause neurocognitive injury, endocrinopathies, and otot...

Guess What Is in My Brain

Catherine Joseph, MSN, APN, AGACNP-BC

Magnetic resonance imaging (MRI) of the brain is an important diagnostic tool used by neurologists. This article explores the workup and management for a patient with a brain lesion and highlights the importance of neuroimaging. Similari...

Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective

Jared Thorley,(1) APRN, MSN, FNP, and Saneese Stephen,(2) MPAS, PA-C, MPA

Prostate cancer is the second most common cause of cancer-related mortality among men in the United States, with an estimated 34,700 deaths annually. Androgen deprivation therapy (ADT) is the cornerstone of advanced prostate cancer thera...

Capecitabine for Salvage Treatment of Patients With Heavily Pretreated Human Papillomavirus–Associated Oropharynx Cancer With Distant Metastases

Anna C. Cooper, PA-C, Casey A. Fazer, PA-C, Ashish V. Chintakuntlawar, MBBS, PhD, Harry E. Fuentes Bayne, MD, MS, Patrick W. McGarrah, MD, and Katharine A. R. Price, MD

Background: Patients with metastatic human papillomavirus–associated oropharyngeal cancer (HPV-OPC) have a median overall survival exceeding 2 years and are often candidates for multiple lines of palliative therapy. With the approval of ...

Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib

Anna Jones,(1) FNP-C, Paola Degregorio,(2) PA-C, Max W. Sung,(3) MD, 
Zahra Ramji,(4) BSN, Min Ren,(5) PhD, and Ari D. Baron,(1) MD

Aims: Advanced practice providers (APPs) play a vital role in monitoring for and managing adverse reactions (ARs). As lenvatinib ARs can resemble cirrhosis (commonly presenting with hepatocellular carcinoma [HCC]), APP input is important...

Clinical Utility of the 31-Gene Expression Profile Test on the Management of Cutaneous Melanoma by Nurse Practitioners and Physician Assistants

Renata Block,(1) MMS, PA-C, Deborah Patterson,(2) MMS, PA-C, Jennifer J. Siegel,(2) PhD, Brian Martin,(2) PhD, Ann P. Quick,(2) PhD, and Jillian Hunt,(3) MSN, APRN, FNP-C, AOCNP®

Objective: The 31-gene expression profile (31-GEP) can predict the risk of recurrence and metastasis in cutaneous melanoma (CM). We assessed the viewpoints and use of 31-GEP testing by physician assistants (PAs) and nurse practitioners (...

Pancreatic Cancer and the Family Connection: The Role of Advanced Practitioners in Screening and Educating Genetically At-Risk Individuals

Tracy Lowe,(1) PhD, MS, RN, Jane DeLuca,(1) PhD, MS, RN, CPNP-PC, Ludovico Abenavoli,(2) MD, PhD, MSc, and Luigi Boccuto,(1) MD

Pancreatic cancer is the third leading cause of cancer deaths in the United States. It has a 95% mortality rate within 5 years of the initial diagnosis. Pancreatic ductal adenocarcinoma is the most commonly diagnosed histotype. The avera...

Surgical Management of Gastrointestinal Stromal Tumors

Heather Townsend, MPAP, PA-C

Gastrointestinal stromal tumors (GISTs) are considered rare, but they are one of the most common malignant mesenchymal tumors within the gastrointestinal tract, affecting 4,000 to 6,000 adults in the United States each year. Because gast...

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors

Mary Heery, APRN, AOCNS®, CBCN

Tamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamo...

Quality of Life in Adult Cancer Patients With Underage Children: An Integrative Review

Gabriela Mota-George, MSN, APRN, FNP-BC, AOCNP®, Ashley Martinez, DNP, APRN, FNP-BC, AOCNP®, CBCN, CPHQ, NEA-BC, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FNAP, FAANP

As many as 24.7% of cancer patients are also parents to children younger than 18 years of age. This population faces unique challenges, and quality of life in parental cancer patients has not been well studied. This integrative review as...

Hyperammonemia Secondary to 5-Fluorouracil

Ashley Scott,(1,2) RN, BSN, OCN®, Sreenivas V. Rao,(2) MD, and Mary Lou Affronti,(1) DNP, RN, MHSc, ANP, FAAN

5-fluorouracil (5-FU) is one of the most common adjuvant antineoplastic agents used in the treatment of localized and metastatic colon cancer. Frequent side effects of 5-FU include myelosuppression, mucositis, nausea, vomiting, and diarr...

Can You Establish the Cause of This Patient’s Shortness of Breath?

Allison Trail, PA-C, Jane Rogers, PharmD, BCOP, and Jaffer Ajani, MD

Mr. B is a 56-year-old man diagnosed with metastatic HER2-positive gastroesophageal adenocarcinoma. He received front-line leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) and trastuzumab for 10 months before restaging imaging reveal...

Distress in Neuro-Oncology Patients and Its Implications for Communication

Carolin Roos,(1) Johannes Weller,(1) MD, Christiane Landwehr,(1) Anja Sciermoch,(2) Cathrina Duffy,(1) MD, Karoline Kohlmann,(1) MD, Christina Schaub,(1) MD, Theophilos Tzaridis,(1) MD, Matthias Schneider,(2) MD, Patrick Schuss,(2) MD, Ulrich Herrlinger,(1) MD, and Niklas Schäfer,(1) MD

Psychoemotional distress affects patients with cancer, including patients with a diagnosis of a malignant brain tumor. Empathy, professional expertise, and conversational skills are required to ensure successful communication with patien...

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib

Sandra Brackert,(1) NP, and Kathleen Polson,(2) NP

Gastrointestinal stromal tumors (GISTs) are considered rare, yet they represent the most common sarcomas of the gastrointestinal tract. The development of tyrosine kinase inhibitors (TKI) for the treatment of GISTs changed the way we tre...

Heart Failure in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor

Amy Henderson, ANP-BC, AOCNP®, and Salwan Al Mutar, MD

Patients with neuroendocrine malignancy with liver metastases are at risk for carcinoid heart disease which, if left unchecked, can lead to heart failure. This case study demonstrates a clinical situation in which an advanced practitione...

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer

Presented by Marcie Beasley, FNP-C, AOCNP®, and Brooke Daniel, MD

HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters di...

Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology

Presented by Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO, Sandra E. Kurtin,(2) PhD, ANP-C, AOCN®, FAPO, and Rasheda Persinger,(3) MSN, AGNP-C, AOCNP®

In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biom...

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC

Presented by Narjust Florez (Duma), MD, and Stephanie McDonald, NP

The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from ...

Managing the Patient With Multiple Primary Tumors

Presented by Holly Chitwood, DNP, APRN, FNP, AGACNP, and Tamara Carey, MSN, APRN, FNP

Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types withou...

Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events

Courtney R. Arn,(1) APRN-CNP, Kimberly J. Halla,(2) MSN, FNP-C, and Sally Gill,(3) RN (Hons)

Tisotumab vedotin-tftv, an antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, demonstrated clinically meaningful and durab...

Using Pleomorphic Adenoma Gene 1 (PLAG1) to Distinguish Carcinoma of the Parotid Gland From Primary Lung Cancer: A Case Study

Avigayil East, DNP

A 40-year-old female never-smoker with no significant medical history presented with right-side facial swelling and 3 months of progressive, radiating otalgia. This article reviews the case of a young woman with carcinoma ex pleomorphic ...

Indeterminate Thyroid Nodules: When to Worry?

Amanda Tibbels, MPAS, PA-C

Indeterminate thyroid nodules can present a confounding scenario for both provider and patient. Once a diagnosis of an indeterminate thyroid nodule is made, appropriate management can range from conservative observation to surgical resec...

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy

Holly Kinahan, MSN, ANP-C, AOCNP®

KRAS mutations are the most common alteration in human cancers, accounting for approximately 30% of mutations in multiple cancer types, including colorectal, pancreatic, non–small lung cancer, and ovarian. Of these, the KRAS p.G12C mutat...

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

Neda Alrawashdh,(1,2) PhD, PharmD, Ali McBride,(3) PharmD, MS, BCPS, Mok Oh,(1) PhD, PharmD, Nimer Alkhatib,(1) PhD, PharmD, Christopher Lee,(4) PhD, RN, FAHA, FAAN, FHFSA, Jennifer Martin,(5) MA, Karen MacDonald,(6) PhD, RN, and Ivo Abraham,(1,3,6) PhD, RN

Background: Pegfilgrastim is recommended to be administered at least 24 hours following the completion of chemotherapy, yet some clinicians use a same-day administration protocol. In this meta-analysis, we compared the incidence of chemo...

Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study

Dan Beverly Fu,(1) DNP, MBA, NP-C, Xiao-Tang Kong,(1) MD, PhD, Tener Goodwin Veenema,(2) PhD, MPH, MS, Daniela A. Bota,(1) MD, PhD, and Binu Koirala,(3) PhD, MGS, RN

Background and Purpose: Clinical guidelines suggest that prophylactic antiepileptic drugs (AEDs) should be given to newly diagnosed seizure-naive brain tumor patients for up to 1 week after craniotomy. Yet, data suggest that prophylactic...

Liquid Biopsy for Guiding Treatment Decisions in Advanced Non–Small Cell Lung Cancer

Gretchen Suk, DMSc, PA-C

Lung cancer is the leading cause of cancer-related deaths in the United States. The 5-year survival rates are poor with traditional therapy alone. New scientific advances in technology involving the human genome, including diagnostic too...

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma

Gwen Hua,(1) PharmD, Daniel Carlson,(2) DO, and Jacqueline R. Starr,(1) PharmD, BCOP

Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of ...

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib

Ashley Martinez,(1) DNP, APRN, FNP-BC, AOCNP®, CBCN, CPHQ, NEA-BC, Tiffany Jones,(2) MSN, ACNP-BC, Joanne C. Ryan,(3) PhD, RN, Chad M. Barnett,(3) PharmD, BCOP, Elpitha L. Soussou,(3) PharmD, MBA, and Sarah Donahue,(4) MPH, NP, AOCNP®

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has demonstrated strong efficacy with manageable side effects for patients with germline breast cancer susceptibility genes 1 or 2 (gBRCA1/2)-mutated, human epidermal gro...

Ultrasound Evaluation of Carotid Artery Intima-Media Thickness: Effective Early Marker of Carotid Artery Disease in Adult Head and Neck Cancer Patients After Neck Radiation?

Whitney Randolph, APRN, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FNAP, FAANP

Radiation is a recommended front-line treatment for many adult head and neck cancer (HNC) patients. Early identification of radiation-associated carotid artery disease (CAD), a well-known phenomenon, can minimize long-term sequelae. This...

Genitourinary Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Emily Lemke, DNP, AGPCNP-BC, AOCNP®

Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of the Medical College of Wisconsin Cancer Center, comments on MET and CTLA-4 inhibitors for clear cell renal cell carcinoma, maintenance targeted therapy for patients with metastatic urothelial carci...

Gynecologic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital/Brown University, interprets data presented at the 2022 ASCO Annual Meeting on rucaparib maintenance in advanced ovarian cancer, single-agent trabectedin in BRCA-positive ova...

Head and Neck Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Heidi Mason, DNP, ACNP-BC

Heidi Mason, DNP, ACNP-BC, of the University of Michigan School of Nursing, considers research on avoiding concurrent chemotherapy in patients with nasopharyngeal carcinoma being treated with radiotherapy and a clinical trial on concurre...

Melanoma: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Suzanne McGettigan, MSN, CRNP, AOCN®

Suzanne McGettigan, MSN, CRNP, AOCN®, of Abramson Cancer Center of the Hospital of the University of Pennsylvania, reviews data on adjuvant therapy in stage IIB or IIC melanoma and omitting lymph node dissection and adjuvant therapy in p...

Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Jacquelyn Lauria, RN, APN, AOCNP® and Rose DiMarco, PharmD, BCPS, BCOP

Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast can...

Gastrointestinal Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN® and Kristen O’Hagan, MSN, ANP-BC, AOCNP®

Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on RAS wild-type metastatic colorectal cancer, locally advanced mismatch repair–deficient rectal cancer, circulating tumor DNA tests, pancreatic neuroe...

Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung ...

Barriers to Adherence to Cancer Treatments Among Head and Neck Cancer Patients

Jennifer Lynn Miller, PhD, RN, CMSRN, and Julianne Evers, DNP, APRN, AGACNP-BC, CCRN

Head and neck cancer patients often undergo a demanding treatment schedule requiring radiation and chemotherapy. Adherence to these treatment schedules is affected by several issues, including socioeconomic factors, characteristics of th...

The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer

Alisha Desai,(1) PharmD, and Sandra Cuellar,(2) PharmD, BCOP, FHOPA, FASHP

Capmatinib and tepotinib received US Food and Drug Administration (FDA) approval for mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping alteration in 2020 and 2021, respectively. Capmatinib was FDA approved in May 2020 un...

Improving Cancer Care Delivery: Learnings for Oncology Nurses and Patient Navigation From a National Quality Survey

Jennifer Aversano,(1,2) MSN, RN, OCN®, BMTCN®, Leigh M. Boehmer,(3) PharmD, BCOP, and Alexander Spira,(4,5) MD, PhD, FACP

Background: Although implementation of patient navigation programs in clinical practice is widespread, heterogeneity exists in the design and delivery of these services. Greater clarity is required on competencies of personnel, delineati...

Solid Pseudopapillary Neoplasm: A Single Institutional Case Series of a Rare Pancreatic Tumor

Kristen Oase,(1) MS, PA-C, Cheryl Meguid,(1) DNP, ACNP, Atsushi Oba,(1,2) Mohammed H. Al-Musawi,(1) MD, MSc, FIBMS-CTV, FRCS (Glasg), Alison Sheridan,(1) MD, Evan Norris,(1) MD, Sanjana Mehrotra,(1) MD, Mark A. Lovell,(3) MD, Richard D. Schulick,(1) MD, MBA, FACS, Steven A. Ahrendt,(1) MD, and Marco Del Chiaro,(1) MD, PhD, FACS

Purpose: Solid pseudopapillary neoplasms (SPN) are rare pancreatic cystic neoplasms with low malignant potential that tend to occur in young women. Due to the rarity of this disease, there are few large case series in the literature, and...

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

Jessica Davis,(1) PharmD, BCOP, CPP, and Megan Wayman,(2) PharmD

The treatment landscape for metastatic melanoma has changed dramatically over the past few years as new medications have been developed. Encorafenib, a B-Raf protein kinase inhibitor, and binimetinib, a MEK inhibitor, were approved by th...

Multidisciplinary Management of Resectable Early-Stage Non-Small Cell Lung Cancer

Jennifer Jacky,(1) MSN, ARNP, AOCNP®, Kristin DeGroot,(2) PA-C, and Rebecca Denney,(2) PA-C

During JADPRO Live Virtual 2021, three advanced practitioners—in surgery, radiation oncology, and medical oncology—discussed their collaboration in the management of resectable early-stage non–small cell lung cancer. The presenters discu...

Immunotherapy for the Treatment of Triple-Negative Breast Cancer

Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®

At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the curren...

Updates in Cholangiocarcinoma

Kristen O’Hagan, MSN, RN, ANP-BC, AOCNP®

Cholangiocarcinoma is a spectrum of invasive adenocarcinomas that arise in the intrahepatic, perihilar, or distal biliary tree, and is classified by location. During JADPRO Live Virtual 2021, Kristen O’Hagan, MSN, RN, ANP-BC, AOCNP®, dis...

Updates in the Management of Renal Cell Carcinoma

Kirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-C

At JADPRO Live Virtual 2021, advanced practitioner experts reviewed clinical updates in the treatment of renal cell carcinoma, key patient counseling and monitoring considerations, and best practices to manage adverse events associated w...

Lung Cancer Biomarker Speak: Teach Me the Language

Beth Sandy,(1) MSN, CRNP, and Jennifer Morrissette,(2) PhD, FACMG

A vital role of the advanced practitioner is to analyze biomarker testing reports and explain to patients how the results may impact their treatment. At JADPRO Live Virtual 2021, presenters reviewed the importance of molecular testing in...

Multidisciplinary Management of Pancreatic Cancer

Pelin Cinar, MD, MS, and Patricia Zendejas, MSN, ANP-C, AOCNP®

At JADPRO Live Virtual 2021, presenters reviewed the epidemiology of pancreatic cancer, treatment options for patients with different stages of pancreatic cancer, and the most common symptoms and complications related to pancreatic cance...

Evidence-Based Criteria Supporting Early Discharge for Pediatric Patients With Osteosarcoma Receiving High-Dose Methotrexate: A Retrospective Chart Review

Erin Armideo, CRNP, MSN, BSN, RN, CPON, Shannon Froio, BSN, RN, Meredith Johnson, CRNP, MSN, BSN, RN, Alison Tardino-Gingrich, CRNP, MSN, BSN, RN, and Elizabeth Froh, PhD, RN

Purpose: The purpose of this study is to describe the outcomes following the implementation of an early discharge protocol for pediatric patients with osteosarcoma receiving high-dose methotrexate (MTX) to determine if the protocol safel...

Tazemetostat: EZH2 Inhibitor

Rachael Straining, PharmD, and William Eighmy, PharmD

Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that sp...

Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy

Yelena Shames, MS, ACNP-BC, CNRN, CTNL, Mimma Errante, MS, ANP-C, OCN®, and Nana Prempeh Keteku, MS, ANP-BC

Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction, which is characterized by the production of autoimmune antibodies to acetylcholine or muscle-specific kinase receptors, causing an error in transmission of...

Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer

Kimberly Halla, FNP-C

Endometrial cancer is the most common cancer of the female reproductive organs. The American Cancer Society estimates that there will be over 65,950 new cases diagnosed in 2022. According to the National Comprehensive Cancer Network (NCC...

Uterine Leiomyosarcoma

Katherine L. Byar,(1) MSN, APN, BC, BMTCN®, and Tricia Fredericks,(2) MD, MPH

Leiomyosarcoma (LMS) is the most common soft tissue sarcoma in adults and can occur in any part of the body. Uterine leiomyosarcoma (uLMS) is the most common location for LMS, making up 2% to 5% of all uterine malignancies. It is an aggr...

Retroperitoneal Liposarcoma: An Unusual Presentation of a Rare Cancer

Jennifer L. Spicer, MA, PA-C

Retroperitoneal liposarcomas (RLPS) are rare tumors that have variable clinical behavior and complex treatment strategies based on presentation, histopathology, and genomics. Early identification is critical, and complete surgical resect...

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

Patrick J. Fleming Jr., PharmD, BCOP, Sylvia Karpio, PharmD candidate, and Nicholas Lombardo, PharmD candidate

Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. A confirm...

Persistent Fever While on Broad-Spectrum Antibiotics in a Patient With Squamous Cell Carcinoma

Xin Li, CRNP, AOCNP®

For solid tumor patients, acute infectious process is often underestimated, especially when caused by fungal, viral, or other atypical pathogens. Providers should perform a comprehensive infectious workup to rule out uncommon pathogen-in...

Other Solid Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN and Mee-young Lee, MSN, ANP-BC

Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of University of Arizona Cancer Center, considers the implications of a novel monoclonal antibody for nasopharyngeal cancer, and Mee-young Lee, MSN, ANP-BC, of Monter Cancer Center, Northwell, disc...

Gastrointestinal Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN®

Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on single and dual immunotherapy for advanced esophageal squamous cell carcinoma; maintenance therapy for metastatic colorectal cancer; a HER2-targeted...

Genitourinary (Non-Prostate) Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Emily Lemke, DNP, AGPCNP-BC, AOCNP®

Following coverage from The ASCO Post, Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of Medical College of Wisconsin Cancer Center, comments on an adjuvant trial of a checkpoint inhibitor for clear cell renal cell carcinoma (RCC), real-world data...

Gynecologic Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island/Brown University, interprets data on adjuvant chemotherapy for locally advanced cervical cancer, bevacizumab for advanced ovarian cancer, a new treatment opti...

Prostate Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, evaluates research on an investigational radiolabeled small molecule, combination therapy in the treatment of de novo metastatic prostate cancer, and a CYP17-lyase inhibit...

Breast Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Sheeba Cantanelli, MPAS, PA-C

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, discusses results from studies evaluating adjuvant therapy with a PARP inhibitor in BRCA-mutated HER2-negative metastatic breast cance...

Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doubl...

Melanoma: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Lisa Kottschade, APRN, MSN, CNP

With coverage from The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews data on immune therapy after surgery, the combination of the anti–LAG-3 antibody relatlimab and nivolumab, and a 6.5-year update of combination ni...

Nipple-Sparing Mastectomy in Breast Cancer: Impact on Surgical Resection, Oncologic Safety, and Psychological Well-Being

Lisa Parks, MS, APRN-CNP, ANP-BC

Nipple-sparing mastectomy (NSM) is a surgical option to improve patient satisfaction with aesthetic outcome. It can be utilized to decrease body image disturbance by preserving the woman’s skin and areolar complex. Data for cancer treatm...

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma

Doreen Grzelak, NP-C, AOCN®, AGN-BC

Pancreatic cancer is the fourth leading cause of death from cancer in both men and women. Pancreatic cancer is typically diagnosed at an advanced stage and has an overall 5-year survival of approximately 9.3%. The National Comprehensive ...

Kidney Cancer Combinations: Tracking and Treating Symptoms With the Challenge of Combination Therapy

Presented by Kathleen Burns, AGACNP-BC, OCN®

At JADPRO Live Virtual 2020, Kathleen Burns, AGACNP-BC, OCN®, discussed strategies to track and treat symptoms associated with combination therapies for the treatment of renal cell carcinoma. 

A Multidisciplinary Approach to Head and Neck Cancer

Presented by Casey Fazer-Posorske, PA-C

At JADPRO Live Virtual 2020, Casey Fazer-Posorske, PA-C, provided updates in the management of patients with head and neck cancer, including the types of head and neck cancers, their associated treatments and side-effect management, the ...

Developments in Hepatocellular Cancer Treatment

Presented by Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®

The treatment landscape of hepatocellular cancer has changed significantly within the past few years. At JADPRO Live Virtual 2020, Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®, provided an overview of developments in hepatocellular cancer ...

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

Presented by Rasheda Persinger, AGNP-C

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, a...

Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct

Presented by Kristen O’Hagan, ANP-BC, MS, AOCNP®

During JADPRO Live Virtual 2020, Kristen O’Hagan, ANP-BC, MS, AOCNP®, provided an overview of rare gastrointestinal tumors, their presentation, and current treatment algorithms. Ms. O’Hagan also discussed the advanced practitioner’s role...

Sarcoma: Disease Overview and Treatment Updates

Presented by Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS

During JADPRO Live Virtual 2020, Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS, highlighted the clinical features and diagnostic workup of soft-tissue sarcoma and presented on a multidisciplinary approach to treatment planni...

Advanced Prostate Cancer: Considerations for Advanced Practitioners

Presented by Brenda Martone, MSN, ANP-BC, AOCNP®

At JADPRO Live Virtual 2020, Brenda Martone, MSN, ANP-BC, AOCNP®, discussed treatment options available for advanced prostate cancer patients and the role of genetics and genomics in patients with advanced prostate cancer. 

What Is the Cause of This Biliary Stricture?

Caeli Barker, PA-C

This article describes the presentation and workup of a 63-year-old male with a bile duct stricture, followed by a discussion on management.

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer

Kristina F. Byers, PharmD, BCOP

The treatment landscape of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer has been modernized by the identification of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibito...

Is This Patient’s Liver Mass Cancer?

Dietrich Davis, FNP-BC, and Steven H. Wei, MS, MPH, PA-C, DFAAPA

Undiagnosed liver lesions are important findings that can affect the physical and mental well-being of patients. They are usually incidental findings identified while clinicians are performing other imaging tests. It is important for cli...

Development, Implementation, and Patient Perspectives of the Women’s Integrative Sexual Health Program: A Program Designed to Address the Sexual Side Effects of Cancer Treatment

Lori A. Seaborne, MPAS, PA-C, Megan Peterson, DNP, David M. Kushner, MD, Janelle Sobecki, MD, MA, and Joanne K. Rash, MPAS, PA-C

Background: Advanced practitioners (APs) are a growing demographic in survivorship care. One goal of survivorship care is to manage consequences of cancer treatments. Sexual dysfunction from prior therapies can impact quality of life. Ad...

Roadmap to the Enhanced Thoracic Surgical Journey

TaCharra Y. D. Woodard, MSN, APRN, ACNP-BC, AOCNP®, Carla M. Patel, MSN, APRN, ACNP-BC, and Garrett L. Walsh, MD

The Enhanced Recovery Program (ERP) is a comprehensive, multidisciplinary approach that directly impacts the functional recovery and quality of life of patients after surgery. Initiated in 2013 at The University of Texas MD Anderson Canc...

Metastatic Melanoma With Leptomeningeal Disease

Amanda M. Marinova, MS, PA-C, Jennifer L. Reilly, CRNP, BSN, MSN, RN, AANP, Victoria Wong, MS, PA-C, Stephanie Weiss, MD, and Anthony J. Olszanski, MD

Leptomeningeal disease in patients with melanoma historically portends a grim prognosis, with median survival measured in weeks to months. The advent of effective immunotherapy and targeted agents may modify the outcome of such patients....

Oncology Advanced Practitioners and Breast Cancer Prevention

Wendy H. Vogel,(1) MSN, FNP, AOCNP®, Haley Pace,(2) MS, CGC, and Matthew Brignola,(3) PharmD

One in eight American women will be diagnosed with breast cancer. Advanced practitioners in oncology can offer risk assessments, counseling, genetic testing, and make both behavioral and pharmacologic recommendations for breast cancer ri...

Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2– Metastatic Breast Cancer

Kimberly Podsada,(1) MSN, NP-C, Joanne C. Ryan,(2) PhD, RN, and Kristi Orbaugh,(3) RN, MSN, RNP, AOCN®

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy are a preferred treatment option for premenopausal and postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor rec...

Alpelisib: A Novel Therapy for Patients With <em>PIK3CA</em>-Mutated Metastatic Breast Cancer

Tori Wilhoit, PharmD, Jeannie M. Patrick, PharmD, BCOP, and Megan B. May, PharmD, BCOP

In the United States, 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime. Breast cancer death rates are higher for women in the United States than any other cancer, followed by lung cancer (National Cancer Institu...

Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma

Jung Young Kim,(1) DNP, APRN, ANP, Katherine B. Peters,(1) MD, PhD, FAAN, James E. Herndon II,(2) PhD, and Mary Lou Affronti,(1) DNP, RN, MHSc, ANP

Patients with glioblastoma have poor overall survival and experience significant burden from neurologic decline and adverse treatment effects. Despite the well-known benefits of early palliative care integration with oncology care, utili...

Pancreatic Ductal Adenocarcinoma: Characteristics of Tumor Microenvironment and Barriers to Treatment

Sujata Kane,(1) PA-C, Anne Engelhart,(1) ANP-BC, Jessica Guadagno,(1) PA-C, Aaron Jones,(1) ANP-BC, Innis Usoro,(2) and Edith Brutcher,(1) ANP-BC, AOCNP®

Pancreatic ductal adenocarcinoma remains a highly aggressive disease, with a 5-year relative survival rate of 10%. Numerous barriers to treatment exist, such as dense desmoplasia, infiltration of immune suppressor cells, inhibitory cytok...

Breast Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Paula Anastasia,(1) RN, MN, AOCN®, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®

Paula Anastasia, RN, MN, AOCN®, of UCLA Health Medical Center, and Wendy H. Vogel, MSN, FNP, AOCNP®, of Harborside, discuss results from studies evaluating therapies in women with de novo metastatic breast cancer and HER2-positive breast...

Gastrointestinal Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN®

Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was le...

Genitourinary (Non-Prostate) Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Jeannette Hammond, PA-C

Following coverage from The ASCO Post, Jeannette Hammond, PA-C, of Seattle Cancer Care Alliance, comments on the results of practice-changing studies on novel therapies in urothelial cancer and renal cell carcinoma.

Gynecologic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Following coverage by The ASCO Post, Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island, interprets findings from major gynecologic oncology abstracts featured in The ASCO Post and considers takeaways for adva...

Thoracic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews the major abstracts in thoracic cancers from the ASCO20 Virtual Scientific Program using coverage by The ASCO Post and offers considerations for advanced ...

Prostate Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, breaks down abstract summaries published in The ASCO Post on a novel target, imaging agent, and androgen-deprivation therapy for prostate cancer, along with their implicat...

Melanoma: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Lisa Kottschade, APRN, MSN, CNP

With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews clinical data on which patients with metastatic melanoma should receive combination therapy vs. single-agent PD-1 up front, and what to do at the ti...

A Patient-Centered Approach for the Treatment of Fungating Breast Wounds

Karlyn L. Rupert, MPAS, PA-C, and Andrea J. Fehl, CRNP, AOCNP®

Nearly 2% to 5% of locally advanced breast cancers develop a fungating breast wound (FBW). Fungating breast wounds develop when malignant cells infiltrate the skin and cause breakdown, ulceration, and infection. Although systemic and loc...

Using Social Media as a Platform for Increasing Knowledge of Lung Cancer Screening in High-Risk Patients

Aimee Strong,(1) DNP, RN, AGACNP-BC, and Michelle Renaud,(2) RN, PhD

Background: Uptake in lung cancer screening for high-risk patients remains low. Eligible patients may not know that this preventive service is available and covered by insurance. Objectives: The objective of this study was to explore usi...

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion

Danielle B. Dunn, PharmD

Two new targeted agents have been approved for pediatric and adult patients with advanced or metastatic solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation. Larotrectinib and...

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin

Kirollos S. Hanna, PharmD, BCPS, BCOP

The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food &...

Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices

Presented by Jame Abraham, MD, and Kelley D. Mayden, MSN, FNP, AOCNP®

Through expert, case-based discussion, Jame Abraham, MD, and Kelley Mayden, MSN, FNP, AOCNP®, presented existing and emerging data for current and investigational therapies for HER2-positive breast cancer and their associated adverse eve...

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices

Presented by Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®

Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment. 

Improving Outcomes for Patients With Advanced Urothelial Carcinoma

Presented by Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C

At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selectio...

Current and Future Directions for PARP Inhibition

Presented by Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD

Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that incl...

First-Line Therapy for Metastatic Non–Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches

Presented by Joshua Bauml, MD, and Christina Knepley, CRNP

At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding c...

Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes

Presented by Amanda M. Viereck, PA-C, and Anthony J. Olszanski, MD, RPh

Checkpoint inhibitors and oncolytic vaccine therapy have transformed the management of metastatic melanoma. This article presents the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the ...

Improving Outcomes for Patients With Metastatic Colorectal Cancer: Challenges and Strategies

Presented by Leslie A. Swanson,(1) ARNP, and Kathleen Boyle,(2) PA-C

At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for exist...

Precautions for Patients Taking Aromatase Inhibitors

Mary Heery,(1) APRN, AOCNS®, CBCN, Stephen Farley,(2) PharmD, BCOP, Rhett Sparkman,(2) PharmD, John Healy, BS, Pharmd, William Eighmy,(3) PharmD, George Zahrah,(2) MD, and Richard Zelkowitz,(1) MD

Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the bi...

A Tale of Two Sisters: Breast Reconstruction Options for Women With or at High Risk of Breast Cancer

Kathryn Trotter,(1) DNP, CNM, FNP, FAAN, Jennifer K. Plichta,(2) MD, MS, FACS, and Michael Zenn,(3) MD, MBA, FACS

Breast reconstructive surgery has changed significantly over the past decade. The incidence of nipple-sparing procedures and prophylactic mastectomy has also increased significantly as women and their surgeons use shared decision-making ...

Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence

Theresa Wicklin Gillespie, RN, MA, PhD, FAAN

Hormone receptor positivity and early stage diagnosis are generally considered signs of good prognosis in breast cancer. However, breast cancer all too frequently can become resistant to hormone-based therapies, and women can experience ...

Metabolic Syndrome, Exercise, and Cardiovascular Fitness in Breast Cancer Survivors

M. Tish Knobf, PhD, RN, AOCN®, FAAN, and Sangchoon Jeon, PhD

Comorbid illness contributes to poorer cancer outcomes and higher mortality. Metabolic syndrome (MetS) includes a cluster of risk factors that are associated with an increased risk of comorbidities. Routine physical activity represents a...

Implementation of Survivorship Care Plans in Patients With Glioblastoma

Casey B. Brown,(1) DNP, RN, AGPCNP-BC, Deborah Allen,(1) PhD, RN, CNS, FNP-BC, AOCNP®, Christina Cone,(1) DNP, APRN, ANP-BC, AOCNP®, and Susan M. Schneider,(2) PhD, RN, AOCN®, ACNS-BC, FAAN

Background: The outcomes and survival of patients diagnosed with glioblastoma are improving due to advancements in therapy and better symptom management. Focusing on survivorship is an important initiative for these patients. A quality i...

Management of Gastric Outlet Obstruction in a Patient With Gastric Cancer

Irene Thomas Thayil, PA-C

This article describes the evaluation of a patient with gastric cancer that confirms gastric outlet obstruction, followed by a discussion on management. 

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?

Wendy H. Vogel,(1) MSN, FNP, AOCNP®, Ahmed Minhas,(2) MD, and Steven Baumrucker,(1) MD

5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause sever...

Management of Acute Pancreatitis Associated With Checkpoint Inhibitors

Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Terri Cuddahy, RN, MSN, OCN®, and Carolyn Zawislak, MPAS, PA-C

Pancreatitis is a rare immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors (ICIs). It is more often associated with combined immunotherapy than by any single agent. Early signs of pancreatitis may ...

Breast Density and Breast Cancer

Pamela Hallquist Viale, RN, MS, CNS, ANP

Associations Between Cytokine Levels and Long-Term Symptom Development in Head and Neck Cancer Patients

Benjamin Stuart Schultze, PhD, MSN, MEd, ACNP

Cytokines have been associated with the development of cancer cachexia. Cytokine dysregulation is thought to cause cachexia and its associated symptoms by negatively affecting physiological homeostasis. Cytokines that have been associate...

Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea

Rory Randall,(1) CNP, AOCNP®, Bonita Bennett,(2) RN, BSN, Tiffany Valone,(3) PA-C, MS, OT, and Kirsten Blue,(3) PA-C, MS

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors (NETs). Frequently diagnosed in advanced stages, carcinoid syndrome diarrhea negatively impacts patients’ well-being and quality of life. This article will rev...

Treatment of Pregnancy-Associated Breast Cancer

Bernadette Labriola, RN, MSN, FNP-C

Case Study KS is a 33-year-old Caucasian married woman who works full time as an accountant and has one daughter who is 2 years old. She enjoys reading and exercising in her spare time. She initially presented in July 2015 at the age of...

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors

Jordan Gabrielsen,(1) PharmD, Gianna Girone,(1) PharmD, Bonita Bennett,(2) BSN, and Anna Jung,(2) PharmD, BCPS

Abstract Somatostatin analogues (SSAs) are widely used in the long-term treatment of neuroendocrine tumors (NETs) and have a relatively favorable safety profile. However, SSAs are associated with specific side effects that are important...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Non–Small Cell Lung Cancer

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Cent...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer

Jennifer L. Glass, PA-C, MS

Following coverage by The ASCO Post, Jennifer L. Glass, PA-C, MS, of the Mayo Clinic dives into the major findings in prostate cancer from the 2019 ASCO Annual Meeting in Chicago and their implications for advanced practitioners.

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Melanoma

Lisa Kottschade, APRN, MSN, CNP

In recent years, there has been an explosion of therapies for the treatment of melanoma, including BRAF mutation–guided therapy. With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of the Mayo Clinic reviews clinical data su...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gastrointestinal Cancer

Carolyn Grande, CRNP, AOCNP®

Using coverage from The ASCO Post of the ASCO Annual Meeting, Carolyn Grande, CRNP, AOCNP®, of the University of Pennsylvania Health System evaluates study findings in gastrointestinal cancer and discusses what advanced practitioners sho...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Genitourinary (Non-Prostate) Cancers

Jeannette Hammond, PA-C

Jeannette Hammond, PA-C, of the Seattle Cancer Care Alliance comments on major research presented at the ASCO Annual Meeting: a study addressing an unmet need in the metastatic urothelial cancer setting, a study showing no benefit from a...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gynecologic Cancers

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of the Women & Infants Hospital of Rhode Island offers commentary on major gynecologic cancer abstracts featured from the ASCO Annual Meeting by The ASCO Post, including findings in carcinosarcoma of th...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Breast Cancer

Wendy H. Vogel, MSN, FNP, AOCNP®

Wendy H. Vogel, MSN, FNP, AOCNP®, of Wellmont Cancer Institute discusses results from a study in hormone receptor–positive metastatic breast cancer (MONALEESA-7), two studies in the metastatic HER2-positive setting (SOPHIA and NALA), as ...

Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

Kimberly D. Allman,(1) CNP, Joanne C. Ryan,(2) PhD, RN, Andrew Clair,(2) PhD, and Sarah Yenser-Wood,(3) NP

Case Study This patient case is fictional and does not represent events or a response from an actual patient. The authors developed this fictional case for educational purposes only. Brady, a 54-year-old white male, was diagnosed wit...

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations

Andrew Garcia,(1) PharmD, Corey Frahm,(1) PharmD, Joanne M. Jeter,(2) MD, Ivo Abraham,(1) PhD, RN, Setsuko K. Chambers,(3) MD, Janiel M. Cragun,(3) MD, and Ali McBride,(1) PharmD

Abstract The association of BRCA mutation status with hypersensitivity reactions (HSRs) to carboplatin has gained interest in recent years, particularly in patients with ovarian, fallopian tube, and primary peritoneal cancer. The primar...

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Urvi J. Patel, PharmD, MPH, and Sarah Caulfield, PharmD, BCOP

Abstract Prostate cancer is the fourth leading cause of cancer in the United States. Treatment of this oncologic disease involves a variety of different modalities including surgery, radiation, and systemic therapy. Systemic therapy is ...

Breast Cancer in the Transgender Population

Andrea Fehl,(1) FNP-C, MSN, AOCNP®, Shannon Ferrari,(1) PA-C, MPAS, Zoe Wecht,(1) BS, and Margaret Rosenzweig,(2) PhD, FNP-C, AOCNP®, FAAN

Case Study ES is a 41-year-old transgender male who presented to medical oncology as a referral from surgical oncology for T2N0M0 right breast cancer. At that time, he was receiving weekly testosterone injections intramuscularly at 0.25...

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

Emily A. Lemke, DNP, RN, AGPCNP-BC, AOCNP®, Amishi Y. Shah, MD, Matthew Campbell, MD, and Nizar M. Tannir, MD

Abstract Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and respons...

Rucaparib and Niraparib in Advanced Ovarian Cancer

Tyler Redelico, PharmD

Abstract Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy...

Advances in the Treatment of HER2-Positive Breast Cancer

Presented by Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C

Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C, reviewed landmark clinical trials of adjuvant therapies for women with HER2–positive breast cancer and emphasized the key role of advanced practitioners in managing adverse eve...

Surgical Implications for Women With Breast Cancer

Presented by Sherry Goldman, MSN, NP, CBCN

At JADPRO Live 2018, Sherry Goldman, MSN, NP, CBCN, delved into different surgical rationales for lumpectomy, mastectomy, and mastectomy with reconstructions. Ms. Goldman also explored the benefits and disadvantages associated with nippl...

Sequencing Therapies in Renal Cell Carcinoma

Presented by Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®

Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®, explained the use of tyrosine kinase inhibitors in the adjuvant setting in patients with advanced renal cell carcinoma, as well has how to best utilize immunotherapy in this set...

Sequencing of Treatments for Patients With Ovarian Cancer

Presented by Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD

Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD, discussed the indications for the three PARP agents (olaparib, rucaparib, and niraparib) and strategies for managing PARP inhibitor–related side effects.

Multimodal Therapies for Head and Neck Cancer

Presented by Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN

HPV-related head and neck cancer is emerging as an epidemic in the US population. At JADPRO Live, Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, evaluated risk factors and prevention strategies. They also discussed...

Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology

Presented by Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP

Advanced practitioners play an important role in recognizing and treating adverse events caused by multimodality therapies in lung cancer. Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP, detailed strategies f...

Therapeutic Advances in Prostate Cancer

Presented by Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP

Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP, discussed the emerging data regarding the role of genomics in metastatic castration-sensitive and -resistant prostate cancer, as well as strategies to manage the to...

Evolving Therapies in the Clinical Management of Melanoma

Presented by Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD

Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD, shared clinical data supporting the use of emerging targeted therapies and immunotherapies in the treatment of metastatic melanoma.

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C

Abstract Although breast cancer is a heterogeneous disease, approximately 20% to 25% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+...

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

Sarah E. Caulfield, PharmD, BCOP, Christine C. Davis, PharmD, BCOP, and Kristina F. Byers, PharmD, BCOP

Breast cancer is the most frequently diagnosed cancer in women globally. Genetic mutations can increase the risk of developing breast cancer. Inherited germline mutations in BRCA1 and BRCA2 tumor suppressor genes (gBRCAm) account for 5% ...

Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer

Leah Shaw, MSN, RN, AGPCNP-BC, AOCNP®, Angela F. Bazzell, DNP, RN, FNP-BC, AOCNP®, and Joyce E. Dains, DrPH, JD, RN, FNP-BC, FNAP, FAANP

Abstract The management of head and neck cancers (HNC) and esophageal cancer (EC) is complex and often involves multiple modalities of treatment, including chemotherapy, radiation therapy, and surgery. The side effects associated with t...

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer

Jennifer Miles, PharmD, and Yahsin White, PharmD

Abstract The treatment of breast cancer has been revolutionized by the development of HER2-targeted treatments for patients who are HER2 positive. The HER2 protein is present at high levels in about 30% of breast cancer patients. These ...

Trametinib: A Targeted Therapy in Metastatic Melanoma

Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Katherine Benchich, MSN, NP-C, AOCNP®

Abstract Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progressi...

Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis

Tzewah V. Leung, PharmD, BCOP, Mitchell E. Hughes, PharmD, BCPS, BCOP, Christine G. Cambareri, PharmD, BCPS, BCOP, Daniel J. Rubin, PharmD, and Beth Eaby-Sandy, MSN, CRNP, OCN®

Abstract Chemotherapy, and now targeted therapies and immunotherapies, are widely used for the management of patients with all stages of lung cancer. Some challenges present when patients are receiving concomitant hemodialysis for vario...

Enhanced Recovery After Surgery

Lisa Parks,(1) MS, RN, CNP, Meghan Routt,(2) MSN, ANP/GNP-BC, AOCNP®, and Allison De Villiers,(1) MSN, RN, OCN®, ACNS-BC

Abstract Enhanced recovery after surgery (ERAS) is a multimodal perioperative care pathway designed to achieve early recovery for patients undergoing major surgical procedures. Meta-analyses, randomized controlled trials, and large pros...

Development of a Professional Practice Model for Neuro-oncology Advanced Practitioners at an Academic Medical Center: A Quality Improvement Project

Christina K. Cone,(1) DNP, APRN, ANP, AOCNP®, and Mary Lou Affronti,(2) DNP, RN, MHSc, ANP

Abstract In medicine, neuro-oncology practice falls outside the scope of established practice requirements for the specialties of neurology, medical oncology, and neurosurgery, justifying the prerequisite of specialized training to prac...

A Nurse Practitioner’s Experience in the Development and Implementation of a Lung Cancer Screening Program

Aimee Strong, MSN, AGACNP-BC

Abstract Lung cancer screening with low-dose computed tomography of the chest is now a service covered by the Centers for Medicare and Medicaid Services and most private insurers. However, providers may experience many barriers that cou...

Breast Cancer and Body Image Issues

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer

Neratinib following the completion of trastuzumab has been shown to reduce the risk of disease recurrence for patients with HER2-positive early breast cancer in whom extended adjuvant therapy seems advisable. In clinical trials, the most...

Combination Therapies 
in Advanced, Hormone 
Receptor–Positive Breast Cancer

About 17% of women with breast cancer have locally advanced or metastatic disease at the time of diagnosis, and 30% to 40% of women diagnosed with early-stage disease will eventually have recurrence. The majority of breast cancers expres...

Precautions for Patients Taking Tamoxifen

Tamoxifen is a lifesaving treatment for millions of breast cancer patients worldwide. Yet taking tamoxifen may be challenging for some patients due to issues of compliance, drug interactions, and surgical considerations. Educating patien...

Li-Fraumeni Syndrome

Breast Implants and Lymphoma: What Is the Risk for Your Patient?

Comparison of Outcome Measures for Traditional and Online Support Groups for Breast Cancer Patients: An Integrative Literature Review

Abstract Despite widespread use of support groups in the breast cancer patient population, there are heterogeneous outcome measurements and inconsistencies in their perceived benefits. The purpose of this integrative literature review i...

Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer

Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and ma...

Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer

Case Study DE, a 31-year-old premenopausal woman with a nonsignificant medical history, noticed a right breast mass after playing basketball in September 2011. She initially attributed the mass to slight trauma, but after 2 weeks, she r...

Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario

Case Study Betty, a 66-year-old white female, was diagnosed with stage IIB, T2N1M0, estrogen receptor/progesterone receptor–positive, HER2-negative breast cancer in 2007. It was detected on screening mammography when she was age 59, and...

Review of the New American Cancer Society Guidelines for Breast Cancer Screening for Women at Average Risk

When Should I Have a Mammogram? Recent Changes in ACS Mammography Guidelines: Implications for Practice

Beyond BRCA: A Pilot Program to Assess and Improve Knowledge of Pharmacogenomic Testing Among Advanced Practitioners in a Breast Cancer Treatment Setting

To provide the best available evidence-based care to their patients, advanced practitioners (APs) must become proficient in genomic competencies and remain informed regarding the availability of pharmacogenomic tests. Databases, such as ...

New Agents for the Management of Advanced HER2-Positive Breast Cancer

Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners

Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications

Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials. Immunotherapy has ...

Hereditary Aspects of Colorectal Cancer: Mismatch Repair Genes Drive Lynch Syndrome

Lynch syndrome is the most common inherited form of colorectal cancer, affecting approximately 1 in 279 individuals, or 1.2 million people in the United States. It's also associated with a predisposition to endometrial, ovarian, and stom...

Liver Resection in Patients With Synchronous Colorectal Liver and Lung Metastases

Assessment of Overall Survival Benefits in Patients Undergoing Complete Hepatectomy for Synchronous Colorectal Cancer With Liver and Lung Metastases

Clinical Management of Bowel Dysfunction After Low Anterior Resection for Rectal Cancer

Abstract The American Cancer Society estimated that 39,610 new cases of rectal cancer were diagnosed in the United States in 2015. Surgery is the primary treatment for rectal cancer, with the majority of patients undergoing sphincter-pr...

Trifluridine/Tipiracil: Old Drug, New Tricks

Patients Living Longer With Metastatic Colorectal Cancer

Optimal Collaborative Management of Patients With Esophagogastric Cancers

The addition of radiation to preoperative chemotherapy and newer therapeutic combinations add to treatment options for these difficult-to-treat cancers.

Symptom Management for Patients With Esophageal Cancer After Esophagectomy

Case Study KD is a 67-year-old man with a medical history of hypertension, asthma, and a 20-pack/year smoking history who developed progressive dysphagia 8 months ago. Upon consultation with his primary care provider, he underwent an es...

The Relationship Between Zinc and Quality of Life in Patients With Upper GI Cancer on Chemotherapy

Abstract This is a pilot study aimed at evaluating the prevalence of zinc deficiency and how zinc levels affect the quality of life (QOL) of patients with upper gastrointestinal (GI) cancers receiving systemic chemotherapy. The data col...

Management of Advanced Bladder Cancer: An Update

Abstract Bladder cancer is the sixth most common cancer in the United States; therefore, the majority of clinicians working in the oncology setting will care for this patient population. Unfortunately, treatment plans, especially in the...

Advances in the Management of Patients With Urothelial Carcinomas of the Bladder

For more than 30 years, there were no new treatments in bladder cancer. Then, in 2016, there were five drug approvals. JADPRO Live presenters delved into recent advancements and opportunities for improving outcomes for patients with blad...

Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

Case Study Tom, a 75-year-old white male, was recently diagnosed with metastatic renal cell carcinoma (RCC; Tom’s case is not an actual clinical case but has been developed by the authors as an exemplar). Two years prior, he had undergo...

Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers

There are challenges to conducting rare cancer clinical trials due to issues surrounding clinical trial design, patient recruitment, and analysis of the study outcomes. This article highlights the challenges of research and data analysis...

Olaparib in Epithelial Ovarian Cancer

Ovarian Cancer: Current Treatment and Patient Management

Advances in Collaborative Practice for Patients With Head and Neck Cancers

Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newe...

A Descriptive, Longitudinal Study of Quality of Life and Perceived Health Needs in Patients With Head and Neck Cancer

Abstract Patients with head and neck cancer have numerous concerns and symptoms in the first year of posttreatment survivorship and are especially vulnerable at the end of treatment and 1 month posttreatment. This article shares the fin...

Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma

CASE STUDY THA is a 40-year-old immigrant from Myanmar who has been living in the United States for about 6 years. He has a history of hepatitis B virus (HBV) infection for many years, for which he has never received any treatment. He i...

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ...

Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Abstract Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for non–small cell lung cancer (NSCLC) patients with activating EGFR mutations. Erlotinib, gefitinib, afatinib, and osimertinib are appro...

Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study

Case Study RS, a 36-year-old female, presented to the emergency department (ED) of a large academic medical center upon the advice of her primary care provider because of 3 weeks of progressive mental status changes, weakness, and decre...

Alectinib and Brigatinib: 
New Second-Generation 
ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

The treatment of non–small cell lung cancer (NSCLC) has been revolutionized by the discovery of genetic driver mutations and associated targeted therapies. Anaplastic lymphoma kinase (ALK) mutations are present in about 5% of NSCLC cases...

Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non–Small Cell Lung Cancer

Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung

Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.

Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer

Introduction As the official publication of the Advanced Practitioner Society for Hematology and Oncology (APSHO), JADPRO is pleased to offer Part 1 of an accredited educational activity based on the recently concluded APSHO Regional Le...

Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer

Management Strategies for Adverse Events Associated With EGFR TKIs in Non–Small Cell Lung Cancer

Abstract New advances in the treatment of non–small cell lung cancer (NSCLC) have afforded patients longer progression-free survival times, but these therapies are also associated with specific side effects that may not be seen with che...

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer

Abstract For decades, the prognosis for patients with advanced-stage non–small cell lung cancer (NSCLC) was bleak, with chemotherapy offering limited benefit and much toxicity. Now, with mutational testing, new generations of targeted t...

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non–Small Cell Lung Cancer

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Research into the PD-1 pathway has been shown to be valuable in the immune system’s ability to control cancer. Blocking this pathway with targeted therapies such as nivolumab has led to tumor response and control in some patients with no...

Collaborative Practice in the Management of Neuroendocrine Tumors

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

Multidisciplinary clinics for pancreatic cancer such as one established at Johns Hopkins offer advantages in the care of patients with pancreatic cancer. Advanced practitioners can play a role in multidisciplinary care, providing symptom...

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen

Optimizing Outcomes for Patients With Soft-Tissue Sarcoma Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

A multidisciplinary team can help improve the outcomes of patients with any cancer, but particularly so for patients with soft-tissue sarcomas, as discussed at JADPRO Live. During this presentation, MD, PA, and NP colleagues from Moffitt...

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma

Abstract Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regim...

Anisocoria and an Array of Neurologic Symptoms in an Adult With Ewing Sarcoma

Case Study Ms. M, a 50-year-old female, reported a progressive 2-year history of sacral pain that became severe in the 2 to 3 months prior to her diagnosis of Ewing sarcoma (ES) and was initially evaluated by her gynecologist. Her prese...

Case Study of a Young Adult With Ewing Sarcoma

Case Study Maria was a 23-year-old woman who initially presented with a 1-year history of pain in the left heel. Over time, the pain had progressively worsened. Eventually, her foot had swollen, and she had difficulty walking, which req...

Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy

Case Study A 48-year-old gentleman with metastatic melanoma currently receiving the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor, ipilimumab (Yervoy), and the programmed cell death protein 1 (PD-1) inhibitor, nivolumab...

Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma

Novel therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique immune-related advers...

Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab represent a substantial improvement in treating advanced melanoma but are associated with adverse events (AEs) likely related to general immunologic enhancement. T...

Evolving Paradigms in Melanoma Therapy